Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Viverra adipiscing at in tellus integer. Massa eget egestas purus viverra. Sit amet purus gravida quis blandit. Elit scelerisque mauris pellentesque pulvinar pellentesque habitant morbi. Nibh ipsum consequat nisl vel pretium lectus quam id leo. Tortor id aliquet lectus proin nibh nisl condimentum id venenatis. Aliquam sem et tortor consequa.
CTA ButtonAdditional Headline for Section
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Viverra adipiscing at in tellus integer. Massa eget egestas purus viverra. Sit amet purus gravida quis blandit. Elit scelerisque mauris pellentesque pulvinar pellentesque habitant morbi. Nibh ipsum consequat nisl vel pretium lectus quam id leo. Tortor id aliquet lectus proin nibh nisl condimentum id venenatis.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Viverra adipiscing at in tellus integer. Massa eget egestas purus viverra. Sit amet purus gravida quis blandit. Elit scelerisque mauris pellentesque pulvinar pellentesque habitant morbi. Nibh ipsum consequat nisl vel pretium lectus quam id leo. Tortor id aliquet lectus proin nibh nisl condimentum
Publications & Presentations
Date
Title
Source
Feb 16-19, 2022
The synthetic glycan KB295 optimises microbiome composition and function in ulcerative colitis: Results from a proof of principle human study.
DownloadECCO 2022 | European Crohn’s and Colitis Organization
Jun 10-14, 2022
Targeting the Microbiome with KB109 in Mild to Moderate COVID-19 Reduced Healthcare Utilization and Symptom Duration.
DownloadWorld Microbe Forum 2021
Feb 16-19, 2022
The synthetic glycan KB295 optimises microbiome composition and function in ulcerative colitis: Results from a proof of principle human study.
DownloadECCO 2022 | European Crohn’s and Colitis Organization
Jun 10-14, 2022
Targeting the Microbiome with KB109 in Mild to Moderate COVID-19 Reduced Healthcare Utilization and Symptom Duration.
DownloadWorld Microbe Forum 2021
Jun 10-14, 2022
Targeting the Microbiome with KB109 in Mild to Moderate COVID-19 Reduced Healthcare Utilization and Symptom Duration.
DownloadWorld Microbe Forum 2021
Feb 16-19, 2022
The synthetic glycan KB295 optimises microbiome composition and function in ulcerative colitis: Results from a proof of principle human study.
DownloadECCO 2022 | European Crohn’s and Colitis Organization
Jun 10-14, 2022
Targeting the Microbiome with KB109 in Mild to Moderate COVID-19 Reduced Healthcare Utilization and Symptom Duration.
DownloadWorld Microbe Forum 2021
